Drugs / Lidocaine Epinephrine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04991597 | Jan → May 2022 | — | Nicholas Bastidas | Withdrawn | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04085913 Comparator | Sep 2019 → Jun 2024 overdue | parathyroid gland adenoma, thyroid gland disorder | University of Missouri-Columbia | Enrolling by invitation | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lidocaine Epinephrine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04085913 ↗ |